Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 144,68 € (+8,48%). La mediana è 149,72 € (+12,26%).
| Acquista |
26 |
| Mantieni |
11 |
| Vendi |
1 |
Discussioni nella community
- comdirect: PDF-Import kaputt?
Update vom Team: Wir haben den Fehler behoben, der Datei-Import sollte wie gewohnt funktionieren. Falls ihr Parqet noch offen habt, bitte einmal neu laden. Ich wollte, wie seit Jahren, ein…
[No name] a193ea06 V in Schnack 7 30
Notizie Vai al feed delle notizie
Merck & Co raises annual guidance after strong quarter
Merck & Co reported a surprisingly strong third quarter, driven by cancer drugs and animal health products, and raised its 2026 revenue forecast to $66.8–67.3 billion. Quarterly revenue rose 5% to $18.1 billion, while net income fell to just under $5.1 billion due to an impairment. Adjusted earnings per share beat expectations at $2.49, and the full-year adjusted EPS target range was raised to $2.77–2.82. The stock reacted positively, gaining nearly 5% in early trading. » Altro su finanzen.net
Merck raises profit outlook as Keytruda Qlex lifts third-quarter results
Merck beat third-quarter estimates, reporting adjusted EPS of $2.49 and revenue of $18.09 billion, and raised its 2026 adjusted EPS guidance to $2.77–$2.82 (now including a one-time $400 million charge tied to a SciBrunch licensing deal). Keytruda sales reached $8.60 billion, with the newer injectable Keytruda Qlex generating $830 million—above expectations and the highest quarterly take since its 2025 launch. Other products showed strong growth (Winrevair up 93%, Gardasil about $2 billion), while animal health sales were slightly below estimates. » Altro su cnbc.com
Merck buys Silence Therapeutics for around $1.1 billion
Merck is acquiring British biotech Silence Therapeutics at $20 per ADR, implying an enterprise value of about $1.1 billion (roughly €980 million). The offer represents an 82% premium to the 30-day average share price and was approved by Silence; the deal is expected to close in the first quarter of 2027. Silence brings Divesiran, an siRNA drug for polycythaemia vera entering the pivotal Phase III study. Merck will finance the purchase with new loans, bolstering its strategy in rare diseases and specialty medicines. » Altro su manager-magazin.de
Goldman Sachs places Merck & Co. on defensive top list, quarterly results in focus on Oct. 29
Goldman Sachs has counted Merck & Co. among 23 defensive stocks because the share shows lower volatility and delivers a cash‑flow yield of around 5%. Investors are paying 16 times the earnings expected for the next twelve months, and Merck benefited from a price rise of more than 70% over the past twelve months. Short‑term catalysts are study data from partner Moderna on Saturday and Merck’s quarterly report on Oct. 29; technically the stock is consolidating below its 52‑week high but remains above key moving averages. » Altro su deraktionaer.de
Merck & Co. expects production of its personalized cancer vaccine to be shortened
Merck & Co. says production of the personalized cancer vaccine developed with Moderna currently takes around six weeks from tumor sequencing to delivery, but is expected to be accelerated over time. The vaccine targets individual tumor mutations and is being tested in combination with Keytruda; first positive late‑stage data have already been seen in melanoma patients, and further studies are underway in lung, bladder and kidney cancer. CEO Rob Davis emphasizes the complexity but points to controlled processes and preparations for supply chains and the market. Merck also opened the new research center "Advance" with robotics and AI to speed up analysis of biological samples; the stock has recently risen sharply. » Altro su deraktionaer.de
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 15,97 Mld | 9,04% |
| Utile lordo | 11,65 Mld | 5,23% |
| Utile netto | 4,47 Mld | 9,29% |
| EBITDA | 5,39 Mld | 23,11% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 330,53 Mld € |
Numero di azioni | 2,47 Mld |
Massimo/minimo a 52 settimane | 142,39 € - 83,58 € |
Rendimento da dividendo | 2,22% |
Dividendi TTM | 2,96 € |
Beta | 0,22 |
Rapporto P/E | 149,25 |
Rapporto PEG | -1,72 |
Rapporto P/B | 8,13 |
Rapporto P/S | 5,41 |
Profilo aziendale
Merck & Co., Inc. opera come società sanitaria a livello mondiale. Opera attraverso due segmenti, Farmaceutico e Salute Animale. Il segmento Farmaceutico offre prodotti farmaceutici per la salute umana nelle aree di oncologia, cura acuta ospedaliera, immunologia, neuroscienze, virologia, cardiovascolare e diabete, nonché prodotti vaccinali, come vaccini preventivi pediatrici, per adolescenti e per adulti. Il segmento Salute Animale scopre, sviluppa, produce e commercializza farmaci veterinari, vaccini e soluzioni e servizi per la gestione della salute degli animali, oltre a prodotti digitalmente connessi per identificazione, tracciabilità e monitoraggio. Serve grossisti e dettaglianti di farmaci, ospedali e agenzie governative; fornitori di assistenza sanitaria gestita, come organizzazioni di manutenzione della salute (HMO), gestori di benefici farmaceutici e altre istituzioni; nonché medici e distributori per medici, veterinari e allevatori di animali. La società ha collaborazioni con AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; e Gilead Sciences, Inc. per sviluppare e commercializzare congiuntamente trattamenti a lunga durata d'azione contro l'HIV. Merck & Co., Inc. è stata fondata nel 1891 ed ha sede a Kenilworth, New Jersey.
| Nome | Merck & Co., Inc. |
| CEO | Robert Davis |
| Sede centrale | Rahway,
nj Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 02/01/1962 |
| Dipendenti | 74.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | MRK |
XETRA | 6MK.DE |
Frankfurt | 6MK.F |
Düsseldorf | 6MK.DU |
Hamburg | 6MK.HM |
Milan | 1MRKX.MI |
London | 0QAH.L |
SIX | MRKUSD.SW |
München | 6MK.MU |
Wien | MRK.VI |